What is Lifesci Capital’s Estimate for GPCR FY2024 Earnings?

Structure Therapeutics Inc. (NASDAQ:GPCR) – Investment analysts at Lifesci Capital increased their FY2024 earnings per share (EPS) estimates for Structure Therapeutics in a note issued to investors on Wednesday, November 13th. Lifesci Capital analyst M. Belghiti now expects that the company will post earnings per share of ($0.75) for the year, up from their prior estimate of ($0.87). The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.80) per share. Lifesci Capital also issued estimates for Structure Therapeutics’ Q4 2024 earnings at ($0.19) EPS, Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.22) EPS and FY2025 earnings at ($0.82) EPS.

Several other equities analysts also recently issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, September 23rd. JMP Securities lowered their target price on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a research report on Friday, August 9th. Finally, Morgan Stanley started coverage on Structure Therapeutics in a report on Monday, September 23rd. They set an “overweight” rating and a $118.00 target price on the stock. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $86.80.

Structure Therapeutics Price Performance

Shares of NASDAQ GPCR opened at $31.75 on Monday. The company has a 50 day simple moving average of $39.38 and a 200 day simple moving average of $39.80. Structure Therapeutics has a 1 year low of $26.61 and a 1 year high of $66.38. The firm has a market cap of $1.82 billion, a PE ratio of -42.77 and a beta of -3.23.

Hedge Funds Weigh In On Structure Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP grew its holdings in Structure Therapeutics by 2.9% during the 3rd quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock worth $341,015,000 after acquiring an additional 221,851 shares during the period. FMR LLC boosted its position in shares of Structure Therapeutics by 6.7% during the 3rd quarter. FMR LLC now owns 6,128,444 shares of the company’s stock valued at $268,977,000 after purchasing an additional 383,635 shares in the last quarter. Janus Henderson Group PLC grew its stake in Structure Therapeutics by 18.0% during the third quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock worth $173,623,000 after purchasing an additional 602,609 shares during the period. Driehaus Capital Management LLC increased its holdings in Structure Therapeutics by 3.5% in the second quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company’s stock worth $101,204,000 after purchasing an additional 86,833 shares in the last quarter. Finally, Federated Hermes Inc. lifted its stake in Structure Therapeutics by 6.6% in the second quarter. Federated Hermes Inc. now owns 2,407,206 shares of the company’s stock valued at $94,531,000 after buying an additional 150,000 shares during the period. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.